Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …

Abstract Lessons Learned Non‐small‐cell lung cancer (NSCLC) represents 85% of lung
cancer in elderly patients. In the present study performed in the 36 elderly subjects with …

Background Osimertinib is one of the standard first-line treatments for advanced non-small
cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating
EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M …

Background The clinical outcomes of elderly patients with EGFR-mutated non-small cell
lung cancer (NSCLC) who are treated with osimertinib have not been sufficiently evaluated …

Background/Aim: The aim of this study was to evaluate the safety and efficacy of osimertinib
for elderly patients, since the data remain limited. Patients and Methods: A total of 77 …

Objectives Osimertinib is the primary treatment for patients with epidermal growth factor
receptor (EGFR) mutation-positive advanced non-small cell lung cancer. However, evidence …

© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S165-S170 tlcr. amegroups. com the mechanisms of acquired resistance to EGFR …

Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung
cancer (NSCLC) are particularly sensitive to treatment with first-or second-generation EGFR …

Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor
receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence …